Novartis in Slovenia donates computers to help children with distance learning during Covid-19 pandemic

  • Novartis in Slovenia donated computers to elementary schools in Lendava, Ljubljana, Domžale and Prevalje, to help children from socially disadvantaged families follow distance learning during the Covid-19 pandemic.
  • The donation is the result of effective and rapid collaboration between local communities and schools to ensure that computer equipment reaches the students who need it the most. 
  • Building long-term relationships with local communities is an important part of responsible business, one of the foundations of Novartis social responsibilities.
21. 4. 2020

Novartis in Slovenia donated computers, including the necessary software, to children from socially deprived families to provide them with equal opportunities to access education materials and participate in distance learning during the Coovid-19 pandemic. With this donation, Novartis in Slovenia will help five families in each Lendava, Ljubljana, Domžale and Prevalje.

Novartis in Slovenia argues that even in these changed circumstances due to the global health crisis, all children should be given equal opportunities to acquire knowledge. Due to the measures to mitigate the spread of the new coronavirus, classes for Slovenian primary and secondary school students have been carried out at distance for more than a month. A key part of a successful learning process is a functioning computer, which many children do not have due to difficult material circumstances. Novartis in Slovenia therefore provided the necessary computer equipment for twenty students who need it the most. The computers were delivered to the children last week.

»Building long-term relationships and relationships with local communities in areas where Novartis operates, is an important part of our business, therefore we decided to help children from the socially most deprived families in the local communities of which we are part. The already vulnerable social groups are experiencing the current crisis the most. We are aware that only with equal access to distance education, our school children will be able to successfully participate in the learning process, even after they return back to school,« said Gizela Štampar, Head Anti-infectives Lendava, upon handing over the donation.

The excellent cooperation with the local authorities was extremely important in the implementation of the grant. On the advice of the mayors, Novartis in Slovenia contacted the principals of the selected primary schools who ensured that the donation went into the right hands. The computers went to the pupils from the Bilingual Primary School I Lendava, Primary School Hinko Smrekar in Ljubljana, Primary School Vencelj Perko in Domžale and Primary School Franjo Golob Prevalje.

During the pandemic caused by the new coronavirus, Novartis continues to care for the safety of patients and the associates worldwide. In implementing safety measures, they are strongly supported by exemplary cooperation with national and local authorities who help them ensure uninterrupted business operations.

Novartis also contributes to research efforts, ensures a stable supply and price of essential medicines, and provides assistance and support to communities in the countries where it operates. In recent weeks is has provided the Slovenian Red Cross and the Slovenian Association of Friends of Youth USD 500,000 from the Novartis’ Global Fund and donated personal protective equipment and disinfectants to health centres, hospitals, care homes and local communities across Slovenia. 

More information about the Novartis response to COVID-19 is available on and

* * *

Novartis is the leading provider of medicines in Slovenia, where Lek, Novartis Pharma Services and Sandoz, operate. Together we are building and maintaining the reputation of a dynamic, ethical, and trusted pharmaceutical company. Lek develops, manufactures, and markets effective, safe, and high quality medicines and active pharmaceutical ingredients. With our knowledge, quality, and experience we have gained an important role in Novartis' organizational structure, especially in the Novartis Technical Operations, Global Drug Development, Novartis Business Services, and the generic division Sandoz. We are the leading Sandoz development center, and one of the key development sites for technologically complex projects. We invest a great deal in the development, education, and training of our employees. Over the last eight years, the company has created more than 2,700 jobs, making us one of the biggest employers in Slovenia. Novartis invested in Slovenia more than EUR 2.5 billion since 2003. 

About Sandoz
Sandoz, a Novartis division, is a global leader in generic pharmaceuticals and biosimilars. Our purpose is to pioneer access for patients by developing and commercializing novel, affordable approaches that address unmet medical needs. Our ambition is to be the world’s leading and most valued generics company. Our broad portfolio of high-quality medicines, covering all major therapeutic areas, accounted for 2019 sales of USD 9.7 billion. Sandoz is headquartered in Holzkirchen, in Germany’s Greater Munich area.

Sandoz is on Twitter. Sign up to follow @SandozGlobal at

About Novartis
Novartis is reimagining medicine to improve and extend people’s lives. As a leading global medicines company, we use innovative science and digital technologies to create transformative treatments in areas of great medical need. In our quest to find new medicines, we consistently rank among the world’s top companies investing in research and development. Novartis products reach more than 800 million people globally and we are finding innovative ways to expand access to our latest treatments. About 109,000 people of more than 145 nationalities work at Novartis around the world. Find out more at 

* * *

This press release contains statements and conclusions based on projections of Lek’s future business operations. These estimates are derived from the best information currently available. In case these forecasts prove unreliable, the actual results could prove different from those projected.

- end -

For additional information contact:
Katarina Klemenc
Corporate Communications 
Lek Pharmaceuticals d. d.
Phone: +386 1 580 22 43
Fax: +386 1 580 24 32